Arrowhead Pharmaceuticals, Inc. (ARWR) Social Stream
Featured Post From StockTwits About ARWR
$ARWR Goldman meeting with ceo highlights from Goldmanskeezbag, published October 29, 2020
Reiterate more patient data at AASLD in November and engagement with FDA in 2021 to reduce study 2/3 length from 2yr to 1yr
AHA conference in November data for ang3 and apoc3. Lover dose frequency (quarter or semi) and better safety than competition
Enac data in 1H21 with proof of concept at year end 2020. Target 10% of population and those that can't take trikafta so 15% of population total or 25%. Can't tell. Promising preclinical safety profile reiterated. Arolung2 goal of filing cta by 2020ye. Arwr plans to address numerous indications here since lung is target rich (asthma, fibrosis....).
Arohif2 entering clinic mid 2021 and an additional lung asset target in 2021. New extra hepatic every 18-24months. Could work across many tumors and make a franchise!!!!
Partner strategically. 10 assets clinical mid 2021 and 20 by 2023/2024 in order to focus on ang3, apoc3, enac and lung2
Arohsd ph2 pending positive ph1 data 1h21